Completed PHASE2 INTERVENTIONAL 1-arm NCT00050440

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

A Phase 2 Study of ET-743 as Second-Line Therapy in Subjects With Persistent or Recurrent Endometrial Carcinoma

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions Endometrial Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Uterine Neoplasms

Updated 7 times since 2017 Last updated: Jan 7, 2013 Started: Jul 31, 2002 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Endometrial Neoplasms and Genital Neoplasms, Female Urogenital Neoplasms, this trial is completed. The trial is conducted by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and has accumulated 7 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PharmaMar

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Dallas, United States , Lexington, United States , Los Angeles, United States , Maastricht, Netherlands , Miami, United States , Moscow, Russia , Nashville, United States , New York, United States , Obninsk, Russia and 4 more locations